Clinical Trial Update: Efficacy Evaluation of a Commercial Preparation Containing Lactobacillus Casei DG on the Reduction of the Painful Symptoms Related to the Irritable Bowel Syndrome (IBS). A Pilot Clinical Study [Phase 4]

View source ↗

Summary

Phase 4 pilot trial evaluated whether a Lactobacillus casei DG–containing probiotic preparation reduces painful symptoms in irritable bowel syndrome; the study …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Lactobacillus casei DG–containing probiotic preparation (Lactobacillus casei DG)

Snippet

Sponsor: SOFAR S.p.A. | Conditions: Irritable Bowel Syndrome | Phase 4 | Status: COMPLETED